Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting

被引:34
|
作者
Eleftheriadou, Maria [1 ,2 ]
Gemenetzi, Maria [1 ,2 ]
Lukic, Marko [1 ,2 ]
Sivaprasad, Sobha [1 ,2 ]
Hykin, Philip G. [1 ,2 ]
Hamilton, Robin D. [1 ,2 ]
Rajendram, Ranjan [1 ,2 ]
Tufail, Adnan [1 ,2 ]
Patel, Praveen J. [1 ,2 ]
机构
[1] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England
[2] UCL Inst Ophthalmol, London, England
关键词
Aflibercept; AMD; Anti-VEGF; Clinical settings; Ophthalmology; Real-life outcomes; LONG-TERM OUTCOMES; CHOROIDAL NEOVASCULARIZATION; VISUAL OUTCOMES; 7-YEAR OUTCOMES; RANIBIZUMAB; MARINA; EYES; HORIZON; ANCHOR; AMD;
D O I
10.1007/s40123-018-0139-5
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
IntroductionTo report 3-year treatment outcomes with intravitreal aflibercept injections for neovascular age-related macular degeneration (nAMD) in routine clinical practice.MethodsThis was a retrospective, single-centre, non-randomized interventional case series analysis. Data from treatment-naive patients with nAMD treated between 1 October 2013 and 31 February 2014 were included in the analysis. Data including age, gender, vision acuity (VA) measured on Early Treatment of Diabetic Retinopathy Study charts (ETDRS) and injection numbers were recorded. Spectral domain optical coherence tomography (SD-OCT) data including presence or absence of macular fluid and automated central subfield macular thickness (CSMT) at year 1, 2 and 3 were also recorded.ResultsOf the 157 eyes of 148 patients treated, data from 108 eyes of 102 patients were available at 3-year follow-up. The mean (SD) age was 80.6 +/- 8.3years with a mean of 154.5 +/- 5.4weeks follow-up. The mean VA changed from 54.4 +/- 16 letters at baseline to 60.3 +/- 18.1 letters (VA gain 5.9 +/- 13.8 letter gain) at 1year, to 60.8 +/- 17.4 letters (VA gain 6.4 +/- 14.9 letters) at 2years and to 61.0 +/- 16.6 letters (VA gain 6.6 +/- 15.4 letters) at 3years. The reduction in CSMT was 77.9 +/- 101.4 mu m with absence of macular fluid in 71% of eyes. The total mean number of injections was 15.9 +/- 6.1 at year 3.Conclusion p id=Par4 The results suggest that good long-term morphological and functional treatment outcomes can be achieved using aflibercept for nAMD in a clinical setting.
引用
收藏
页码:361 / 368
页数:8
相关论文
共 50 条
  • [21] Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration
    Heussen, Florian M.
    Shao, Qing
    Ouyang, Yanling
    Joussen, Antonia M.
    Mueller, Bert
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 252 (06) : 909 - 915
  • [22] Three-Year Outcomes of Patients with Neovascular Age-Related Macular Degeneration Treated with Aflibercept under the National Health Insurance Program in Taiwan
    Lo, Kang-Jung
    Chang, Jin-Yu
    Chang, Hsin-Yi
    Chiou, Shih-Hwa
    Hwang, De-Kuang
    Chen, Shih-Jen
    JOURNAL OF OPHTHALMOLOGY, 2020, 2020
  • [23] Clinical outcome of switching from ranibizumab to aflibercept in the treatment of neovascular age-related macular degeneration
    Lu, Lin
    Muthulingam, Gnanaruban
    Osborne, Claire
    Tonne, Prabhu
    Reddy, Gopinath
    Logendran, Maharatnam
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [24] One-Year Outcomes of Aflibercept in Recurrent or Persistent Neovascular Age-Related Macular Degeneration
    Arcinue, Cheryl A.
    Ma, Feiyan
    Barteselli, Giulio
    Sharpsten, Lucie
    Gomez, Maria Laura
    Freeman, William R.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2015, 159 (03) : 426 - 436
  • [25] THREE YEAR TREATMENT PATTERNS OF RANIBIZUMAB AND AFLIBERCEPT FOR THE MANAGEMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN ROUTINE CLINICAL PRACTICE IN THE USA
    Leteneux, C.
    Milnes, F.
    Skelly, A.
    Bezlyak, V
    Paschen, E.
    Sagkriotis, A.
    VALUE IN HEALTH, 2016, 19 (07) : A574 - A574
  • [26] Intravitreal aflibercept for neovascular age-related macular degeneration
    Xu, David
    Kaiser, Peter K.
    IMMUNOTHERAPY, 2013, 5 (02) : 121 - 130
  • [27] One-Year Outcomes of Aflibercept in Recurrent or Persistent Neovascular Age-Related Macular Degeneration
    Iacono, Pierluigi
    Parodi, Maurizio Battaglia
    Bandello, Francesco
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2015, 159 (05) : 996 - 997
  • [28] One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
    Rush, Ryan B.
    CLINICAL OPHTHALMOLOGY, 2023, 17 : 2201 - 2208
  • [29] Intravitreal Aflibercept for Treatment-Resistant Neovascular Age-Related Macular Degeneration: 2-year Outcomes
    Le Hong, Thomas Hai
    Broadhead, Geoffrey
    Joachim, Nichole
    Wong, Lily
    Zhu, Meidong
    Chang, Andrew Alexander
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [30] Three-Year Outcomes of Neovascular Age-Related Macular Degeneration in Eyes That Do Not Develop Macular Atrophy or Subretinal Fibrosis
    Gabrielle, Pierre-Henry
    Vuong Nguyen
    Arnold, Jennifer J.
    Bhandari, Sanjeeb
    Viola, Francesco
    Tigchelaar-Besling, Odette A. M.
    Garay-Aramburu, Gonzaga
    O'Toole, Louise
    Cheung, Chui Ming Gemmy
    Barthelmes, Daniel
    Creuzot-Garcher, Catherine
    Gillies, Mark
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2021, 10 (13):